In a publication last week, researchers described efforts to improve in silico methods for investigating the pathogenicity of missense BRCA1/2 variants of unknown significance.
A targeted sequencing analysis of 42 pancreatic ductal adenocarcinoma has uncovered prognostically-relevant germline mutations in 29 percent of sporadic cases.
The firm will provide its genetic testing, counseling, and cascade screening to patients seen at a group of US health systems, focusing on CDC Tier 1 conditions.
A Phase III randomized trial uncovered enhanced carboplatin response in advanced triple-negative breast cancer patients with germline mutations affecting BRCA1/2.
23andMe's Anne Wojcicki writes in an opinion piece at Stat News that people can understand their genetic risk information without the input of experts.
There's an increase in genetic testing for breast cancer risk in Northern Ireland, BBC News reports, adding that better support for those tested is also needed.
23andMe has gotten the OK from the US Food and Drug Administration for its genetic health risk report on three mutations that increase breast cancer risk.
The consumer genomics firm says employer benefits programs could expand access to BRCA1/2, Lynch syndrome, and FH genetic testing in the general population.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
